PPT-Concomitant Antiplatelet and OAC

Tx RealWorld Practice In the US 800000 AF patients are on concomitant OAC and antiplatelet tx 1 Patients on chronic OAC with CAD are 7x more likely to receive concomitant antiplatelet tx. b,c OAc AcO AcO AcO OAc S AcO AcO AcO OAc CMe O S OO CMe S O CMe OMs MsO S O O CMe O S O CMe O Scheme 1. (a) O, 0 (OAC BPG EAD) Maintained by the California Digital Library Version 2.0 April 2005 OAC Working Group, Metadata Standards Subcommittee Reviewed and Updated SemiAnnually Working Group: . Maria E. Wolfs, MD, FRCP; . Rémi. . Rabasa-Lhoret. , MD, PhD. Canadian Cardiovascular Society Antiplatelet . Guidelines. Objectives. Interpret . the . Canadian Cardiovascular Society Guideline recommendations regarding the use of antiplatelet . Therapy for the Primary Prevention of Vascular Events. Working Group: . Alan D. Bell, MD, CCFP and James D. . Douketis. , MD, FRCP. Canadian Cardiovascular Society Antiplatelet Guidelines. Objectives. Antiplatelet Guidelines. HEART FAILURE. Working Group: . Alan D. Bell, MD, CCFP; James D. . Douketis. , MD, FRCP. Objectives. Interpret . the . Canadian Cardiovascular Society Guideline . recommendations . Therapy for Secondary Prevention . Beyond One Year . Following . ACS or PCI. Working Group. : . Anil Gupta MD, FRCPC, Pierre Theroux MD, FRCPC . Canadian Cardiovascular Society Antiplatelet Guidelines. Thomas Savides, M.D.. Professor of Clinical Medicine. University of California, San Diego. Disclosures. None. Learning Objectives. Accurately assess the risk of bleeding in patients on anticoagulants and antiplatelet agents before endoscopic procedures. Robust HT screen. Hit Identification. Chemical and biological validation. Used to study biological processes. Potential . therapeutic. .  .                                                                                                                                                                                                                        . Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. TAVI with atrial fibrillation : which antithrombotic regimen? G. Montalescot (Paris, FR) www.action-cœur.org Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France Presenter: . Meng-Jiun. . Chiou. 5Sep2017. 1. Introduction. Lifelong . antiplatelet. treatment is recommended after . ischaemic. vascular events, on the basis of trials done mainly in patients younger than 75 years. . Anticoagulant therapy. (n = . 124). CADISS. P. rimary outcome. : . Ipsilateral . stroke or all-cause mortality . for antiplatelet vs. anticoagulation: 2. % . vs. 1%; p . = . 0.63. Any stroke: 2% vs. 1%, . . Katherine Belanger BS. 1. , Timothy H. Ung MD. 1. , Denise . Damek. MD. 2. , Kevin O. . Lillehei. MD. 1. , D. Ryan Ormond, MD, PhD. 1. . Department of Neurosurgery, University of Colorado School of Medicine, Aurora, CO, USA. intracerebral haemorrhage (ICH): extended follow-up of the. RE. start. or . ST. op. . A. ntithrombotics. . R. andomised . T. rial. (RESTART) . RESTART Collaboration. www.RESTARTtrial.org. Intracerebral haemorrhage (ICH) is associated with an increased risk of arterial ischaemic events*: pooled analysis of 4 population-based cohorts.